๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Megestrol acetate therapy and secondary adrenal suppression

โœ Scribed by Ko K. Naing; John A. Dewar; Graham P. Leese

Book ID
101230417
Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
63 KB
Volume
86
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

BACKGROUND.

Adrenal suppression has been noted in patients who are receiving medroxyprogesterone acetate (MPA). Megestrol acetate (MA) is used to treat patients with advanced breast carcinoma, cachaexia related to acquired immune deficiency syndrome, and disseminated carcinomatosis, and it is believed to have fewer side effects than MPA. The aim of this study was to test for secondary adrenal suppression in patients receiving MA therapy for advanced metastatic cancer.

๐Ÿ“œ SIMILAR VOLUMES

Megestrol acetate in pediatric oncology
Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression
โœ Lisa M. Orme; Jodie D. Bond; Maureen S. Humphrey; Margaret R. Zacharin; Peter A. ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 282 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Despite the widespread use of megestrol acetate (MA) among a growing number of pediatric oncology departments, there is only one published study on the use of MA in children with malignant disease. The objectives of the current study were to examine the effect of MA in im